Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab
Portfolio Pulse from
Indaptus Therapeutics has initiated a new expansion arm of its Phase 1b/2 clinical trial to evaluate the combination of its drug Decoy20 with BeiGene's PD-1 checkpoint inhibitor, tislelizumab. The study will focus on safety, dose optimization, and early signs of anti-tumor activity.
March 18, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Indaptus Therapeutics has initiated a new phase in its clinical trial, combining Decoy20 with BeiGene's tislelizumab. This could lead to advancements in cancer treatment, focusing on safety and anti-tumor activity.
The initiation of a new phase in the clinical trial suggests progress in Indaptus's drug development, which could positively impact its stock price. The focus on safety and anti-tumor activity is crucial for future success.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100